1/13
04:05 pm
bbot
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1/7
07:00 am
bbot
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Ka Pipeline Programs
Medium
Report
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Ka Pipeline Programs
12/16
04:05 pm
bbot
BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/11
04:05 pm
bbot
BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
12/10
04:05 pm
bbot
BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Ka Breaker, at the San Antonio Breast Cancer Symposium (SABCS)
Low
Report
BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Ka Breaker, at the San Antonio Breast Cancer Symposium (SABCS)
11/18
04:05 pm
bbot
BBOT to Participate in Upcoming December Investor Healthcare Conferences
Medium
Report
BBOT to Participate in Upcoming December Investor Healthcare Conferences
11/12
04:05 pm
bbot
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
Low
Report
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
11/3
04:05 pm
bbot
BBOT to Participate in the Jefferies Global Healthcare Conference in London
Low
Report
BBOT to Participate in the Jefferies Global Healthcare Conference in London
10/30
05:45 pm
bbot
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)
Low
Report
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)
10/25
12:30 pm
bbot
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Ka Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hypergly
Medium
Report
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Ka Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hypergly
10/23
04:05 pm
bbot
BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Low
Report
BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics